{
    "clinical_study": {
        "@rank": "80525", 
        "arm_group": [
            {
                "arm_group_label": "Cohorts A and C", 
                "arm_group_type": "Experimental", 
                "description": "Single dose (D1) followed by twice daily dosing for 7 days"
            }, 
            {
                "arm_group_label": "Cohorts B and D", 
                "arm_group_type": "Experimental", 
                "description": "Single dose (D1) followed by twice daily dosing for 7 days"
            }, 
            {
                "arm_group_label": "Cohorts E and F", 
                "arm_group_type": "Experimental", 
                "description": "Single dose (D1) followed by twice daily dosing for 7 days"
            }, 
            {
                "arm_group_label": "Cohorts G and I", 
                "arm_group_type": "Experimental", 
                "description": "Single dose (D1) followed by twice daily dosing for 7 days"
            }, 
            {
                "arm_group_label": "Cohorts H and J", 
                "arm_group_type": "Experimental", 
                "description": "Single dose (D1) followed by twice daily dosing for 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the single- and multiple-dose pharmacokinetic (PK), safety and tolerability of\n      AVP-786 in healthy volunteers."
        }, 
        "brief_title": "Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult males\n\n          -  18 - 45 years of age\n\n          -  BMI 18 - 30 kg/m2\n\n        Exclusion Criteria:\n\n          -  History or presence of significant disease\n\n          -  History of substance and/or alcohol abuse within the past 3 years\n\n          -  Use of tobacco-containing or nicotine-contining products within 6 months\n\n          -  Use of any prescription of over-the-counter (OTC) medication within 14 days"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01787747", 
            "org_study_id": "12-AVR-132"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohorts A and C", 
                "intervention_name": "AVP-786 Dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohorts B and D", 
                "intervention_name": "AVP-786 Dose 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohorts E and F", 
                "intervention_name": "AVP-786 Dose 1/Q Dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohorts G and I", 
                "intervention_name": "AVP-786 Dose 1/Q Dose 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohorts H and J", 
                "intervention_name": "AVP-786 Dose 2/Q Dose 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohorts A and C", 
                    "Cohorts B and D", 
                    "Cohorts E and F", 
                    "Cohorts G and I", 
                    "Cohorts H and J"
                ], 
                "intervention_name": "AVP-923", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dextromethorphan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pharmacokinetics", 
            "Healthy Volunteers", 
            "dextromethorphan with quinidine", 
            "deuterated dextromethorphan"
        ], 
        "lastchanged_date": "June 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Adelaide", 
                    "country": "Australia", 
                    "state": "South Australia", 
                    "zip": "5000"
                }, 
                "name": "CMAX"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 1, Single-center, Randomized, Double-blind, Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Doses of AVP-786 (Deuterated Dextromethorphan) in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "CMAX", 
            "last_name": "Sepehr Shakib, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Plasma concentrations of parent and metabolites", 
            "safety_issue": "No", 
            "time_frame": "8 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01787747"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessments to include Physical Examination (PE), Labs, ECGs, and Adverse Events (AEs)", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "8 days"
        }, 
        "source": "Avanir Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Avanir Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}